Loading clinical trials...
Loading clinical trials...
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
Conditions
Interventions
Elacestrant
Abemaciclib
Locations
86
United States
Providence Medical Foundation
Fullerton, California, United States
California Research Institute
Los Angeles, California, United States
Carle Cancer Center
Urbana, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Miami Valley Hospital South
Centerville, Ohio, United States
Start Date
August 31, 2022
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
April 6, 2026
NCT06608446
NCT04389632
NCT06966700
NCT07174336
NCT04895709
NCT07191730
Lead Sponsor
Stemline Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions